Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 131Lymphoma 117Lymphoma, Large B-Cell, Diffuse 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Multiple Myeloma 50Lymphoma, Non-Hodgkin 46Lymphoma, Follicular 45Leukemia 39Hodgkin Disease 33Lymphoma, Mantle-Cell 32Burkitt Lymphoma 32Lymphoma, Large-Cell, Immunoblastic 21Lymphoma, Large-Cell, Anaplastic 20Lymphoma, B-Cell, Marginal Zone 19Neoplasm Metastasis 16Leukemia, Lymphocytic, Chronic, B-Cell 16Neoplasms, Plasma Cell 15Neoplasms 13Lymphoma, T-Cell, Peripheral 10Dendritic Cell Sarcoma, Interdigitating 10Recurrence 9Lymphoma, B-Cell 9Primary Myelofibrosis 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoblastic Lymphadenopathy 8Blast Crisis 7Lymphoma, T-Cell 6Graft vs Host Disease 6Waldenstrom Macroglobulinemia 5Prostate Cancer Metastatic 5

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Hormone Refractory Prostate Cancer × Prednisone × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡